Dupilumab’s Big Win: FDA Approves First Treatment for Allergic Fungal Rhinosinusitis

On February 24, 2026, Regeneron and Sanofi announced a major milestone: the FDA approved Dupixent® (dupilumab) for treating adults and children aged 6 and older with allergic fungal rhinosinusitis (AFRS) — a chronic, often debilitating condition that affects patients who’ve already undergone sinus surgery.

This isn’t just another label expansion. It’s the first and only FDA-approved treatment for AFRS in the United States.

For patients who’ve endured repeated surgeries, nasal congestion, and persistent inflammation — often with no effective medical therapy — this approval is a game-changer.

Why This Approval Matters Beyond the Label

Dupilumab, already a blockbuster for asthma, eczema, and chronic rhinosinusitis, is proving its versatility.

AFRS is a niche but serious condition — often misdiagnosed, under-treated, and poorly managed. Patients typically suffer from:

• Recurrent sinus infections
• Nasal polyps
• Loss of smell
• Chronic fatigue

Now, for the first time, they have a targeted, biologic therapy — not just steroids or surgery — to manage their disease.

And with this approval, Sanofi and Regeneron are reinforcing Dupilumab’s position as one of the most versatile biologics on the market — with potential to expand into even more indications in the coming years.

The Biosimilar Race Is On — And It’s Global

While the innovators celebrate, biosimilar developers are already lining up.

Here’s who’s in the race — and where they stand:

• Alvotech — Partnered with Advanz for commercialization in Europe and other markets. AVT19 (dupilumab biosimilar) is in development.
• Samsung Bioepis — Added dupilumab biosimilar to its pipeline in January 2026.
• Chong Kun Dang — Received EMA and UK MHRA approval for phase 1 trials of CKD-706 (dupilumab biosimilar).
• CSPC Pharmaceutical — Cleared by China’s NMPA to begin clinical trials.
• Bio-Thera Solutions & SteinCares — Agreement to commercialize biosimilar dupilumab across Latin America.
• Binnopharm Group & Mabwell — MOU to localize production in Russia and the EAEU.

This isn’t just about cost savings — it’s about global access. As biosimilars enter the market, they’ll bring Dupilumab’s benefits to patients in regions where the originator is too expensive or unavailable.

What This Means for the Biologics Market

Dupilumab’s new approval and the biosimilar pipeline highlight two key trends:

1. Biologics Are Becoming More Adaptable
   Once seen as “one disease, one drug,” biologics like dupilumab are now being tested — and approved — for multiple indications. This extends their commercial life and justifies R&D investment.

2. Biosimilars Are No Longer a “Future Threat” — They’re Here
   With multiple players already in clinical trials or commercial partnerships, the biosimilar wave is accelerating. And it’s not just in the U.S. or EU — it’s global, from Latin America to Russia to China.

For pharma companies, this means:

• Innovators must keep innovating — new indications, delivery methods, combo therapies.
• Biosimilar developers must move fast — but also navigate complex regulatory landscapes.
• Payers and patients will benefit — more competition, more access, lower prices.

The Bottom Line: Dupilumab Is Just Getting Started

This FDA approval isn’t the end of Dupilumab’s journey — it’s a new chapter.

For patients, it’s hope.
For innovators, it’s validation.
For biosimilar developers, it’s a starting gun.

And for the biologics market? It’s a reminder that the future belongs to drugs that can evolve — and to companies that can adapt.

Because in 2026, the race isn’t just about who gets to market first. It’s about who can stay relevant — long after the first approval.